Severity of doxorubicin-induced small intestinal mucositis is regulated by the TLR-2 and TLR-9 pathways

Journal of Pathology

Volumn 226, Issue 4, 2012, Pages 598-608

  Kaczmarek, Agnieszka ^a   Brinkman, Brigitta M ^a   Heyndrickx, Liesbeth ^a   Vandenabeele, Peter ^a   Krysko, Dmitri V ^a  

^a GHENT UNIVERSITY   (Belgium)

Author keywords

apoptosis; chemotherapy induced mucositis; ileitis; inflammation; small intestine damage

Indexed keywords

2 (2,4 DICHLOROPHENYL) 3 (1 METHYL 3 INDOLYL)MALEIMIDE; DOXORUBICIN; GLYCOGEN SYNTHASE KINASE 3BETA; IMMUNOMODULATING AGENT; ODN 2088; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 9; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL COUNT; CONTROLLED STUDY; DISEASE SEVERITY; ENTERITIS; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME REPRESSION; FEMALE; HISTOLOGY; ILEUM; INTESTINE INJURY; INTESTINE VILLUS; LAMINA PROPRIA; LEUKOCYTE; MOUSE; NEUTROPHIL CHEMOTAXIS; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; SMALL INTESTINE DISEASE; SMALL INTESTINE MUCOSA; WILD TYPE;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; CHEMOTAXIS, LEUKOCYTE; DOXORUBICIN; ENZYME INHIBITORS; FEMALE; GLYCOGEN SYNTHASE KINASE 3; ILEUM; INDOLES; INTESTINAL MUCOSA; LEUKOCYTES; MALEIMIDES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MUCOSITIS; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTOR 4;

EID: 84856691714     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.3009     Document Type: Article

References (51)

1. Blijlevens NM, Donnelly JP, De Pauw BE,. Mucosal barrier injury: biology, pathology, clinical counterparts and consequences of intensive treatment for haematological malignancy: an overview. Bone Marrow Transplant 2000; 25: 1269-1278. (Pubitemid 30428142)
2. Elting LS, Cooksley C, Chambers M, et al., The burdens of cancer therapy. Clinical and economic outcomes of chemotherapy-induced mucositis. Cancer 2003; 98: 1531-1539. (Pubitemid 37151510)
3. van der Velden WJ, Herbers AH, Feuth T, et al., Intestinal damage determines the inflammatory response and early complications in patients receiving conditioning for a stem cell transplantation. PLoS One 2010; 5: e15156.
4. Sonis ST,. The pathobiology of mucositis. Nature Rev Cancer 2004; 4: 277-284. (Pubitemid 38525283)
5. Sonis ST,. New thoughts on the initiation of mucositis. Oral Dis 2010; 16: 597-600.
6. Logan RM, Gibson RJ, Bowen JM, et al., Characterisation of mucosal changes in the alimentary tract following administration of irinotecan: implications for the pathobiology of mucositis. Cancer Chemother Pharmacol 2008; 62: 33-41. (Pubitemid 351537842)
7. Logan RM, Stringer AM, Bowen JM, et al., Is the pathobiology of chemotherapy-induced alimentary tract mucositis influenced by the type of mucotoxic drug administered? Cancer Chemother Pharmacol 2009; 63: 239-251.
8. Blijlevens NM, Lutgens LC, Schattenberg AV, et al., Citrulline: a potentially simple quantitative marker of intestinal epithelial damage following myeloablative therapy. Bone Marrow Transplant 2004; 34: 193-196. (Pubitemid 39136824)
9. Lutgens LC, Blijlevens NM, Deutz NE, et al., Monitoring myeloablative therapy-induced small bowel toxicity by serum citrulline concentration: a comparison with sugar permeability tests. Cancer 2005; 103: 191-199. (Pubitemid 39665473)
10. Cario E, Rosenberg IM, Brandwein SL, et al., Lipopolysaccharide activates distinct signaling pathways in intestinal epithelial cell lines expressing Toll-like receptors. J Immunol 2000; 164: 966-972. (Pubitemid 30043724)
11. Vaishnava S, Behrendt CL, Ismail AS, et al., Paneth cells directly sense gut commensals and maintain homeostasis at the intestinal host-microbial interface. Proc Natl Acad Sci U S A 2008; 105: 20858-20863.
12. Podolsky DK, Gerken G, Eyking A, et al., Colitis-associated variant of TLR2 causes impaired mucosal repair because of TFF3 deficiency. Gastroenterology 2009; 137: 209-220.
13. Bogunovic M, Dave SH, Tilstra JS, et al., Enteroendocrine cells express functional Toll-like receptors. Am J Physiol Gastrointest Liver Physiol 2007; 292: G1770-G1783. (Pubitemid 47080591)
14. Chabot S, Wagner JS, Farrant S, et al., TLRs regulate the gatekeeping functions of the intestinal follicle-associated epithelium. J Immunol 2006; 176: 4275-4283. (Pubitemid 44264407)
15. Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F, et al., Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell 2004; 118: 229-241. (Pubitemid 38962578)
16. Vora P, Youdim A, Thomas LS, et al., Beta-defensin-2 expression is regulated by TLR signaling in intestinal epithelial cells. J Immunol 2004; 173: 5398-5405. (Pubitemid 39392123)
17. Kawai T, Akira S,. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nature Immunol 2010; 11: 373-384.
18. Fukata M, Vamadevan AS, Abreu MT,. Toll-like receptors (TLRs) and Nod-like receptors (NLRs) in inflammatory disorders. Semin Immunol 2009; 21: 242-253.
19. Beurel E, Michalek SM, Jope RS,. Innate and adaptive immune responses regulated by glycogen synthase kinase-3 (GSK3). Trends Immunol 2010; 31: 24-31.
20. Martin M, Rehani K, Jope RS, et al., Toll-like receptor-mediated cytokine production is differentially regulated by glycogen synthase kinase 3. Nature Immunol 2005; 6: 777-784. (Pubitemid 43090463)
21. Beurel E, Jope RS,. The paradoxical pro- and anti-apoptotic actions of GSK3 in the intrinsic and extrinsic apoptosis signaling pathways. Prog Neurobiol 2006; 79: 173-189. (Pubitemid 44331500)
22. Hofmann C, Dunger N, Scholmerich J, et al., Glycogen synthase kinase 3-beta: a master regulator of toll-like receptor-mediated chronic intestinal inflammation. Inflamm Bowel Dis 2010; 16: 1850-1858.
23. Chen L, Shi W, Li H, et al., Critical role of toll-like receptor 9 in morphine and Mycobacterium tuberculosis-induced apoptosis in mice. PLoS One 2010; 5: e9205.
24. He L, Li H, Chen L, et al., Toll-like receptor 9 is required for opioid-induced microglia apoptosis. PLoS One 2011; 6: e18190.
25. Li Y, Li H, Zhang Y, et al., Toll-like receptor 2 is required for opioids-induced neuronal apoptosis. Biochem Biophys Res Commun 2011; 391: 426-430.
26. Keefe DM, Brealey J, Goland GJ, et al., Chemotherapy for cancer causes apoptosis that precedes hypoplasia in crypts of the small intestine in humans. Gut 2000; 47: 632-637.
27. de Koning BA, van Dieren JM, Lindenbergh-Kortleve DJ, et al., Contributions of mucosal immune cells to methotrexate-induced mucositis. Int Immunol 2006; 18: 941-949. (Pubitemid 43983289)
28. Imaeda AB, Watanabe A, Sohail MA, et al., Acetaminophen-induced hepatotoxicity in mice is dependent on Tlr9 and the Nalp3 inflammasome. J Clin Invest 2009; 119: 305-314.
29. Coghlan MP, Culbert AA, Cross DA, et al., Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. Chem Biol 2000; 7: 793-803.
30. Thotala DK, Geng L, Dickey AK, et al., A new class of molecular targeted radioprotectors: GSK-3beta inhibitors. Int J Radiat Oncol Biol Phys 2010; 76: 557-565.
31. Krysko DV, Vanden Berghe T, Parthoens E, et al., Methods for distinguishing apoptotic from necrotic cells and measuring their clearance. Methods Enzymol 2008; 442: 307-341.
32. Krysko DV, Kaczmarek A, Krysko O, et al., TLR-2 and TLR-9 are sensors of apoptosis in a mouse model of doxorubicin-induced acute inflammation. Cell Death Differ 2011; 18: 1316-1325.
33. Duramad O, Fearon KL, Chang B, et al., Inhibitors of TLR-9 act on multiple cell subsets in mouse and man in vitro and prevent death in vivo from systemic inflammation. J Immunol 2005; 174: 5193-5200. (Pubitemid 40593156)
34. Cohen P, Frame S,. The renaissance of GSK3. Nature Rev Mol Cell Biol 2001; 2: 769-776. (Pubitemid 33679839)
35. Calcaterra C, Sfondrini L, Rossini A, et al., Critical role of TLR9 in acute graft-versus-host disease. J Immunol 2008; 181: 6132-6139.
36. Heimesaat MM, Nogai A, Bereswill S, et al., MyD88/TLR9 mediated immunopathology and gut microbiota dynamics in a novel murine model of intestinal graft-versus-host disease. Gut 2010; 59: 1079-1087.
37. Zhou R, Wei H, Sun R, et al., Recognition of double-stranded RNA by TLR3 induces severe small intestinal injury in mice. J Immunol 2007; 178: 4548-4556. (Pubitemid 46492407)
38. Cario E, Gerken G, Podolsky DK,. Toll-like receptor 2 controls mucosal inflammation by regulating epithelial barrier function. Gastroenterology 2007; 132: 1359-1374. (Pubitemid 46627595)
39. Lee J, Mo JH, Katakura K, et al., Maintenance of colonic homeostasis by distinctive apical TLR9 signalling in intestinal epithelial cells. Nature Cell Biol 2006; 8: 1327-1336. (Pubitemid 44835107)
40. Jones RM, Sloane VM, Wu H, et al., Flagellin administration protects gut mucosal tissue from irradiation-induced apoptosis via MKP-7 activity. Gut 2011; 60: 648-657.
41. Vijay-Kumar M, Aitken JD, Sanders CJ, et al., Flagellin treatment protects against chemicals, bacteria, viruses, and radiation. J Immunol 2008; 180: 8280-8285.
42. Burdelya LG, Krivokrysenko VI, Tallant TC, et al., An agonist of toll-like receptor 5 has radioprotective activity in mouse and primate models. Science 2008; 320: 226-230. (Pubitemid 351521417)
43. Abreu MT,. Toll-like receptor signalling in the intestinal epithelium: how bacterial recognition shapes intestinal function. Nature Rev Immunol 2010; 10: 131-144.
44. Into T, Kiura K, Yasuda M, et al., Stimulation of human Toll-like receptor (TLR) 2 and TLR6 with membrane lipoproteins of Mycoplasma fermentans induces apoptotic cell death after NF-kappa B activation. Cell Microbiol 2004; 6: 187-199. (Pubitemid 38111599)
45. Jung DY, Lee H, Jung BY, et al., TLR4, but not TLR2, signals autoregulatory apoptosis of cultured microglia: a critical role of IFN-beta as a decision maker. J Immunol 2005; 174: 6467-6476. (Pubitemid 40663842)
46. Jope RS, Johnson GV,. The glamour and gloom of glycogen synthase kinase-3. Trends Biochem Sci 2004; 29: 95-102. (Pubitemid 38186580)
47. Akira S, Takeda K,. Toll-like receptor signalling. Nature Rev Immunol 2004; 4: 499-511. (Pubitemid 38931765)
48. Woodgett JR, Ohashi PS,. GSK3: an in-Toll-erant protein kinase? Nature Immunol 2005; 6: 751-752. (Pubitemid 43090457)
49. Kanzler H, Barrat FJ, Hessel EM, et al., Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nature Med 2007; 13: 552-559. (Pubitemid 46830615)
50. Obermeier F, Strauch UG, Dunger N, et al., In vivo CpG DNA/toll-like receptor 9 interaction induces regulatory properties in CD4 + CD62L+ T cells which prevent intestinal inflammation in the SCID transfer model of colitis. Gut 2005; 54: 1428-1436. (Pubitemid 41375200)
51. Obermeier F, Dunger N, Strauch UG, et al., CpG motifs of bacterial DNA essentially contribute to the perpetuation of chronic intestinal inflammation. Gastroenterology 2005; 129: 913-927. (Pubitemid 41242684)